Filing Flows › TriSalus Life Sciences (TLSI) › Q1 2026 › vs Q4 2025
TriSalus Life Sciences (TLSI) Q1 2026 vs Q4 2025 (quarter over quarter)
TriSalus Life Sciences's revenue fell $4.3M (-33%) from $13.2M in Q4 2025 to $8.9M in Q1 2026.
TriSalus Life Sciences, Q1 2026: revenue $8.9M (-3% year over year), operating margin -94.5%, net earnings $1.5M, operating cash flow −$6.5M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $8.9M | $13.2M | −$4.3M | -33% |
| Other income, net | $10.0M | −$6.5M | $16.4M | — |
| Costs & expenses | $18.9M | $23.0M | −$4.1M | -18% |
| Operating costs | $17.3M | $16.5M | $834K | +5% |
| Income tax | $4K | $0 | $4K | — |
| Net earnings | $1.5M | −$9.8M | $11.3M | — |
| Cost of revenue | $1.2M | $1.8M | −$532K | -30% |
| Research & development | $3.2M | $2.6M | $646K | +25% |
| Sales & marketing | $7.4M | $8.0M | −$560K | -7% |
| General & admin | $5.5M | $4.2M | $1.3M | +31% |
| Operating cash sources | $10.6M | −$4.9M | $15.6M | — |
| Depreciation & amortization | $135K | $126K | $9K | +7% |
| Share-based compensation | $2.5M | $2.2M | $275K | +13% |
| Cash used in operations | $6.5M | $2.5M | $4.0M | +161% |
| Working capital & other | $10.6M | −$4.9M | $15.6M | — |
Questions
How much did TriSalus Life Sciences's revenue grow quarter over quarter in Q1 2026?
TriSalus Life Sciences's revenue fell $4.3M (-33%) from $13.2M in Q4 2025 to $8.9M in Q1 2026.